ASH 2022 Abstracts

ASH 2022 ABSTRACTS
ABSTRACT
WEB LINK
LEAD AUTHORSENIOR AUTHORMER DATALEO DATA
953 FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphomahttps://doi.org/10.1182/blood-2022-157194 MaurerCerhanyesyes
2860 Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)https://doi.org/10.1182/blood-2022-160351 WrightRimszayesno
724 Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCLhttps://doi.org/10.1182/blood-2022-159620 WenzlNovakyesno
1541 Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphomahttps://doi.org/10.1182/blood-2022-170228 StokesGandhiyesno
2957 Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortiumhttps://doi.org/10.1182/blood-2022-157083 DayLinkyesyes
2889 Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphomahttps://doi.org/10.1182/blood-2022-167633 TawfiqYucaiCReWEno
2900 Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Settinghttps://doi.org/10.1182/blood-2022-165419 GileYucaiCReWEno
1591 Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Studyhttps://doi.org/10.1182/blood-2022-164988 RuanFeldmanyesyes
4156 Molecular Landscape of Primary Refractory DLBCLhttps://doi.org/10.1182/blood-2022-156497 BockNovakyesno
545 A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Studyhttps://doi.org/10.1182/blood-2022-167466 HerveCerhanyesno
2966 Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Studyhttps://doi.org/10.1182/blood-2022-169575 KhuranaMaureryesno
850 Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysishttps://doi.org/10.1182/blood-2022-169433 KhuranaNowakowskinoyes
4207 Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Grouphttps://doi.org/10.1182/blood-2022-162688 AlduruccioLossosnoyes
798 Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Erahttps://doi.org/10.1182/blood-2022-165207 DesaiCerhanyesno
793 Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphomahttps://doi.org/10.1182/blood-2022-164692 LuanMartinyesyes
313 Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortiumhttps://doi.org/10.1182/blood-2022-164720 RoddayParsonsyesno
Hypomagnesemia in Untreated Diffuse Large B-cell Lymphomahttps://doi.org/10.1182/blood-2022-156361 GileWitzigyesno